Trevi gains FDA alignment on Phase 3 IPF-cough program; cash $188.3M

Trevi Therapeutics, Inc.

FDA alignment on Phase 3 program for IPF-related chronic cough; first Phase 3 trial to start Q2 2026.
Cash, cash equivalents $188.3M at year-end 2025; expected runway into 2028.
Q4 2025 net loss $8.3M vs $11.4M in Q4 2024; FY2025 net loss $42.8M.
R&D expenses Q4 $6.2M down from $9.3M; G&A $4.0M up from $2.9M.
Plan to initiate Phase 2b trial for refractory chronic cough in Q2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Trevi Therapeutics, Inc. reported for the quarter and year ended December 31, 2025 results: net income $42.8 million.

Period: for the quarter and year ended December 31, 2025
Net income: $42.8 million
Result: reported results

Exact text from the filing

For the year ended December 31, 2025, the Company reported a net loss of $42.8 million, compared to a net loss of $47.9 million in 2024.

View on SEC.gov

Browse all earnings releases →

Trevi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-110767

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.